Patent intelligence · US
US 9132138
Method for the treatment of multiple sclerosis
Method for the treatment of multiple sclerosis
Patent details — US 9132138
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 15, 2015
- Expiration
- Sep 10, 2035
- Applicant
- CASI Pharmaceuticals, Inc
- Claims
- 27
- CPC classes
- A61K, A61K31/385, A61K31/565, A61K38/215
Quick answer
US 9132138 (Method for the treatment of multiple sclerosis) is held by CASI Pharmaceuticals, Inc. Status: granted. Granted Sep 15, 2015. Expires Sep 10, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CASI Pharmaceuticals, Inc
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/385, A61K31/565, A61K38/215, A61K39/0008, A61K45/06
More from CASI Pharmaceuticals, Inc
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 9132138?
US 9132138 (Method for the treatment of multiple sclerosis) is held by CASI Pharmaceuticals, Inc. Status: granted. Granted Sep 15, 2015. Expires Sep 10, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9132138?
CASI Pharmaceuticals, Inc is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 9132138 expire?
Our index shows an expiration date of Sep 10, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.